VYNE Therapeutics
VYNE
VYNE
52 hedge funds and large institutions have $161M invested in VYNE Therapeutics in 2018 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 5 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.12% more ownership
Funds ownership: 0.86% → 0.99% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Holders
52
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$12.8M | |
| 2 | +$9.03M | |
| 3 | +$5.9M | |
| 4 |
O
OrbiMed
New York
|
+$4.66M |
| 5 |
JPMorgan Chase & Co
New York
|
+$4.62M |
Top Sellers
| 1 | -$10.1M | |
| 2 | -$9.08M | |
| 3 | -$1.74M | |
| 4 |
D.E. Shaw & Co
New York
|
-$231K |
| 5 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
-$200K |